Effects of exercise on AKT/PGC1-α/FOXO3a pathway and muscle atrophy in cisplatin-administered rat skeletal muscle

Jun Hyun Bae1,*, Dae Yun Seo2,*, Sang Ho Lee1, Chaeyoung Shin1, Parivash Jamrasi1, Jin Han2,*, and Wook Song1,4,*

1Health and Exercise Science Laboratory, Institute of Sports Science, Seoul National University, Seoul 08826, 2National Research Laboratory for Mitochondrial Signaling, Department of Physiology, College of Medicine, Smart Marine Therapeutics Center, Cardiovascular and Metabolic Disease Center, Inje University, Busan 47392, 3Department of Taekwondo, Dong-A University, Busan 49315, 4Institute of Aging, Seoul National University, Seoul 08826, Korea

ARTICLE INFO
Received July 9, 2021
Revised August 19, 2021
Accepted August 26, 2021

*Correspondence
Jin Han
E-mail: phyhanji@inje.ac.kr
Wook Song
E-mail: songw3@snu.ac.kr

Key Words
Autophagy
Cisplatin
Exercise training
Muscle atrophy
Skeletal muscle

ABSTRACT Cisplatin has been reported to cause side effects such as muscle wasting in humans and rodents. The physiological mechanisms involved in preventing muscle wasting, such as the regulation of AKT, PGC1-α, and autophagy-related factor FOXO3a by MuRF 1 and Atrogin-1, remain unclear following different types of exercise and in various skeletal muscle types. Eight-week-old male Wistar rats (n = 34) were assigned to one of four groups: control (CON, n = 6), cisplatin injection (1 mg/kg) without exercise (CC, n = 8), cisplatin (1 mg/kg) + resistance exercise (CRE, n = 9) group, and cisplatin (1 mg/kg) + aerobic exercise (CAE, n = 11). The CRE group performed progressive ladder exercise (starting with 10% of body weight on a 1-m ladder with 2-cm-interval grids, at 85°) for 8 weeks. The CAE group exercised by treadmill running (20 m/min for 60 min daily, 4 times/week) for 8 weeks. Compared with the CC group, the levels of the autophagy-related factors BNIP3, Beclin 1, LC3-II/I ratio, p62, and FOXO3a in the gastrocnemius and soleus muscles were significantly decreased in the CRE and CAE groups. The CRE and CAE groups further showed significantly decreased MuRF 1 and Atrogin-1 levels and increased phosphorylation of AKT, FOXO3a, and PGC1-α. These results suggest that both ladder and aerobic exercise directly affected muscle wasting by modulating the AKT/PGC1-α/FOXO3a signaling pathways regardless of the skeletal muscle type.

INTRODUCTION
Cisplatin is a highly effective anticancer drug used to treat patients with bladder, head, neck, lung, ovarian, and testicular cancers [1]. The most common adverse effects of cisplatin treatment in patients with cancer are muscle weakness and fatigue due to skeletal muscle mass depletion [2]. Specific muscular atrophy induced by cisplatin treatment is associated with autophagy activation. Previous studies showed that the forkhead box O3 (FOXO3a) transcription factor was retained in the nucleus following dephosphorylation of Thr32 and Ser253, leading to promotion of the transcription of autophagy-related factors including lipitated microtubule-associated protein 1 light chain 3 (LC3), p62, and Beclin 1 and activation of muscle atrophy through muscle RING finger protein 1 (MuRF 1) and Atrogin-1, which are involved in muscle wasting [3-5]. Particularly, Atrogin-1 and MuRF 1 accelerate skeletal muscle atrophy following cisplatin treatment in human and animals [1,6-8].

In animal models, cisplatin treatment was shown to stimulate cell autophagy in fast-twitch skeletal muscle by downregulating the Akt and phosphorylated FOXO3a signaling pathways [9,10]. Combining exercise with cisplatin treatment can prevent muscle atrophy by altering the autophagy signaling pathway. Exercise is also related to the expression of AMP-activated protein kinase-regulated skeletal muscle protein metabolism as well as increased levels of autophagy-related FOXO3a during cisplatin treat-
Exercise-preserved muscle mass and function during cisplatin treatment was shown to be associated with the regulation of autophagy [12]. In previous study, aerobic exercise performed during cisplatin treatment attenuated body weight loss by 50% and maintained lean body mass and muscle grip strength [13]. In addition, seven weeks of aerobic exercise protected against cell death in C57BL6 male mice treated with a single injection of cisplatin [14], and cisplatin administered to fast-twitch skeletal muscle affected autophagy by decreasing the levels of protein kinase B (AKT) and phosphorylated FOXO3a [15]. However, the impact of different exercise types (e.g., aerobic and resistance exercise) on autophagy and muscle atrophy factors, particularly on the levels of AKT, peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), and FOXO3a, in different muscle fiber types (e.g., type I and type II muscle) is not well-understood.

In clinical studies, mice are typically treated with 1 mg/kg cisplatin, which affects levels of autophagy factors [16,17]. Previous studies showed that aerobic exercise prevents muscle atrophy; however, different exercise types and the key mediator autophagy factor FOXO3a have not been evaluated in different skeletal muscle types [1,18,19]. Exercise has been shown to increase PGC-1α and AKT, suggesting that exercise can potently regulate autophagy-related factors in cisplatin-induced muscle wasting [20,21]. Therefore, this study was conducted to evaluate the effect of two different exercise types— aerobic and resistance exercise—on the expression levels of various autophagy-related factors, including FOXO3a, Beclin 1, BCL2-interacting protein 3 (BNIP3), and the LC3-II/I ratio, as well as on muscle atrophy. Atrophy was assessed by measuring the expression levels of 4EBP1, MuRF 1, and Atrogin-1 in rats treated with the current standard cisplatin dosage. We hypothesized that different aerobic and resistance exercises would decrease the expression levels of autophagy-related factors and muscle atrophy following cisplatin treatment.

**METHODS**

**Animal care and experimental protocols**

All experiments were approved by the Institutional Animal Use and Care Committee of Inje University (Busan, Korea: IACUC approval No. 2018-013). Seven-week-old male Wistar rats (n = 34) were purchased from Orient Bio (Seongnam, Korea) and housed at a temperature of 23°C and humidity of 40%–60%, with a 12:12-h light–dark cycle. The rats were fed a standard diet and water *ad libitum*. After one week of acclimatization, the rats were randomly assigned to one of four groups subjected to different treatments and/or exercise regimes: control group (CON, n = 6), administered only saline injections; CC group (n = 8), administered cisplatin injections (1 mg/kg) without exercise; CRE group (n = 9), administered cisplatin (1 mg/kg) + resistance exercise; CAE group (n = 11), administered cisplatin (1 mg/kg) + aerobic exercise. The animals were administered cisplatin (1 mg/kg) once daily for three days [15] and allowed to adapt to their environment for one week prior beginning aerobic exercise and resistance training. During this week, rats in the CAE group were familiarized with treadmill running (1050-RM, Exer-3/6 treadmill; Columbus Instruments, Columbus, OH, USA) four times per week at a pace of 20 m/min for 15 min. During the first week after familiarization, the rats exercised by treadmill running at 10 m/min on a 0% gradient for 10 min/day. The exercise intensity was gradually increased to 20 m/min on a 0% gradient for 60 min/day over eight weeks [22]. During the week following the three-day treatment regime, rats in the CRE group were placed on a 1-m ladder with a 2-cm interval grid at an 85° angle five times per week. Resistance exercise training was progressively increased by 10% of the body weight each week [23] for 60 min/day over eight weeks. All rats were euthanized by intraperitoneal injection of alfaxalone and then dissected. The experimental procedure is illustrated in Fig. 1. The gastrocnemius (GAS) and soleus (SOL) muscle tissues were collected and frozen in liquid nitrogen for storage at –80°C until analysis.

![Fig. 1. Experimental procedure of the study.](https://doi.org/10.4196/kjpp.2021.25.6.585)
Western blotting

We extracted total protein from the GAS and SOL muscle tissues using RIPA buffer (#89900; Thermo Fisher Scientific, Waltham, MA, USA) containing phosphatase inhibitor (#4906845001; Sigma-Aldrich, St. Louis, MO, USA) and protease inhibitor (#4693159001; Roche, Basel, Switzerland). Proteins were separated using 10%–16% Tris-glycine sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred onto nitrocellulose membranes using iBlot 2 Transfer Stacks (#IB23002; Invitrogen, Carlsbad, CA, USA). The following primary antibodies were used: LC3 (#L7543) and p62 (126M4796V) from Sigma-Aldrich; BNIP3 (#3769), Beclin 1 (#3738), FOXO3a (#2497), p-FOXO3a (#8174), AKT (#4691), p-AKT (#9271), mTOR (#2972), p-mTOR (#5536), 4EBP1 (#9644), and p-4EBP1 (#9459) from Cell Signaling Technology (Danvers, MA, USA); and PGC1-α (#SC-518025; Santa Cruz Biotechnology, Dallas, TX, USA). Each primary antibody was incubated with a peroxidase-conjugated secondary anti-rabbit antibody (#7074; Cell Signaling Technology), and specific antibodies were detected using Immobilon Western Chemiluminescent HRP Substrate (#WBKLS0500; MilliporeSigma, Billerica, MA, USA). The band densities were normalized to that of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which was used as an internal control.

Statistical analyses

All data are presented as the mean ± standard deviation. Statistical analyses were performed using GraphPad Prism version 9.1.0 software (GraphPad, Inc., San Diego, CA, USA). Different groups were evaluated using one-way analysis of variance and Tukey's honestly significant difference test for post-hoc analysis. A p-value of ≤ 0.05 was considered to indicate a statistically significant difference.

RESULTS

Exercise improved autophagy-related protein levels in skeletal muscle

Western blot analysis of the GAS muscle samples (Fig. 2) from the CRE and CAE groups revealed lower levels of the autophagy-related proteins Beclin 1 (Fig. 2B: F = 148.40, p < 0.001), p62 (Fig. 2D: F = 18.20, p < 0.001), and BNIP3 (Fig. 2F: F = 85.83, p < 0.001) and a lower LC3-II/I ratio (Fig. 2H: F = 36.32, p < 0.001) compared to in the CC group. In addition, FOXO3a was significantly up-regulated in both the CRE and CAE groups (Fig. 2C: F = 69.06, p < 0.001). Western blot analysis of the SOL muscle samples (Fig.
3) showed that Beclin 1 levels were downregulated (Fig. 3B: F = 78.27, p < 0.001), the LC3-II/I ratio was decreased (Fig. 3F: F = 28.21, p < 0.001), and p62 levels were downregulated (Fig. 3D: F = 11.42, p < 0.001) in both the CRE and CAE groups, whereas FOXO3α was upregulated in these groups (Fig. 3C: F = 37.49, p < 0.001). BNIP3 (Fig. 3E: F = 22.05, p < 0.001) levels in the SOL muscle samples were upregulated in the CRE group but did not differ significantly from those in the CC group.

**Exercise increased AKT, mTOR, and PGC1-α levels in skeletal muscle of cisplatin-induced rats**

The phosphorylation of AKT (Fig. 2I: F = 13.03, p < 0.001), mTOR (Fig. 2H: F = 87.22, p < 0.001), and PGC1-α (Fig. 2J: F = 298.90, p < 0.001) showed a greater increase in the GAS muscle samples from the CRE and CAE groups (Fig. 2) than in those from the CON and CC groups. In the SOL muscle (Fig. 3), phosphorylated mTOR showed greater upregulation only in the CRE group compared to the CON group (Fig. 3H: F = 26.78, p < 0.001). In addition, PGC1-α (Fig. 3I: F = 119.10, p < 0.001) exhibited greater upregulation in the CAE and CRE groups than in the CC and CON groups. Based on these results, exercise interventions may increase mitochondrial biogenesis in cisplatin-induced rats.

**Exercise regulated AKT/PGC1-α/FOXO3α signaling pathways in skeletal muscle of cisplatin-induced rats**

We investigated the effects of PGC1-α-regulated FOXO3α activation on the skeletal muscle of cisplatin-induced rats. In both the GAS (Fig. 2) and SOL (Fig. 3) muscles subjected to cisplatin treatment, the AKT/FOXO3α signaling pathways were modulated, which can result in increased autophagy. The p-FOXO3α/FOXO3α ratios in the cisplatin-induced skeletal muscle of the CC group were significantly decreased. Thus, both aerobic and resistance exercise improved the deficiency of autophagy-related factors in cisplatin-treated skeletal muscle by regulating the AKT/PGC1-α/FOXO3α signaling pathway.

**AKT/PGC1-α/FOXO3α signaling pathway directly affected 4EBP1, MuRF 1, and Atrogin-1 levels following exercise training**

As shown in Fig. 4, the GAS (Fig. 4B: F = 32.16, p < 0.001) and SOL (Fig. 4F: F = 20.41, p < 0.001) muscle samples from the CRE and CAE groups showed significantly upregulated levels of phosphorylated 4EBP1 compared to those in the GAS (Fig. 4C: F = 6.06, p < 0.01) and SOL muscle (Fig. 4G: F = 47.85, p < 0.001) in the CRE and CAE groups. Therefore, muscle protein synthesis increased...
Exercise modulates autophagy related proteins in cisplatin induced rats

Korean J Physiol Pharmacol 2021;25(6):585-592

www.kjpp.net

via upregulation of 4EBP1 following exercise, leading to decreased muscle atrophy.

DISCUSSION

We examined the role of autophagy-related factors during cisplatin administration combined with exercise and found that both resistance and aerobic exercise improved the autophagy-related factor expression and reduced muscle atrophy, with no apparent differences between the exercise types.

In cisplatin-treated GAS muscle, the Beclin 1, p62, and BNIP3 levels were downregulated and LC3-II/I ratio was decreased in the CRE group compared to in the CC group (Fig. 2B, D–F). These factors were also downregulated in the CAE group relative to in the CC group, except for p62 (Fig. 2B, E, F). Moreover, phosphorylation of FOXO3a in the GAS and SOL muscles following cisplatin treatment was upregulated in both the CRE and CAE groups (Figs. 2C and 3C). These results are supported by the upregulation of Beclin 1, LC3-II, and p62, and FOXO3a has been shown to transcriptionally activate autophagy and several autophagy-related genes as well as LC3 and Beclin 1 in a cisplatin-treated model [15,24,25]. Our results also showed that exercise modulated the expression of autophagy-related factors and may be involved in the adaptation of autophagy-related factors in the muscle and increased levels of oxidative proteins [26].

Our findings were supported by those of a previous study showing that 6 weeks of aerobic exercise did not affect skeletal muscular inflammation and glucose tolerance but preserved muscle mass in cisplatin-administered mice [13]. In addition, in a cisplatin-administered mouse model, phosphorylation of AKT and FOXO3a was increased and myostatin (Mstn) gene expression was attenuated in the quadriceps and gastrocnemius [27]. Another previous study indicated that only aerobic exercise can protect against muscle atrophy by altering the levels of MuRF 1 and Atrogin-1; however, our findings indicate that resistance exercise in cisplatin-administered rats did not dramatically affect MuRF 1 and Atrogin-1 levels compared with aerobic exercise training. This may be because aerobic exercise training is more reliant on degradation of the ubiquitin proteasome pathway marker FOXO3a compared to in resistance training [28].

We found that AKT, FOXO3a, and PGC1-α expression levels were higher in the GAS and SOL muscles following cisplatin treatment in the CRE and CAE groups than in the CC group (Fig. 2C, I, J; Fig. 3C, I, J). A previous study showed that the AKT/PGC1-α/FOXO3a signaling pathway decreased autophagy-related factors, including BNIP3, LC3, Beclin 1, and p62 [1], during cisplatin treatment. We found that the level of phosphorylation of AKT, PGC1-α, and FOXO3a was increased by both resistance and aerobic training, leading to downregulation of BNIP3, Beclin 1, and p62 and a decrease in the LC3-II/I ratio. PGC1-α regulates autophagy [29], and exercise-induced AMP-activated protein

Fig. 4. Expression levels of muscle atrophy-related proteins including 4EBP1, Atrogin-1, and MuRF 1, in the gastrocnemius and soleus muscles. (A, E) Representative bands. (B) Phospho-4EBP1/total 4EBP1 in gastrocnemius, (C) Atrogin-1/GAPDH in gastrocnemius, (D) MuRF 1/GAPDH in gastrocnemius, (F) phospho-4EBP1/total 4EBP1 in soleus, (G) Atrogin-1/GAPDH in soleus, and (H) MuRF 1/GAPDH in soleus. CON, control (n = 6); CC, cisplatin control (n = 8); CRE, resistance exercise with cisplatin treatment (n = 9); CAE, aerobic exercise with cisplatin treatment (n = 11). MuRF 1, muscle RING finger protein 1; Atrogin-1, muscle-specific F-box protein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. One-way analysis of variance and Tukey’s post-hoc were used for statistical analysis; units are arbitrary. *p < 0.05, **p < 0.01, ***p < 0.001.
kinase decreases the regulation of FOXO3a, which can in turn decrease the transcription levels of LC3, p62, and BNIP3 [30-33]. These findings also suggest that increased PGC1-α levels help prevent autophagy in the skeletal muscles caused by cisplatin-induced cytotoxicity [20]. A previous study demonstrated that patients with cancer treated with chemotherapy showed no changes in the skeletal fiber type distribution after 10 weeks of exercise [34], which agrees with our results, revealing similar responses in the expression levels of AKT, PGC1-α, and FOXO3a in the GAS and SOL muscles. Our findings indicate that exercise training directly affects the phosphorylation of FOXO3a and overexpression of PGC1-α to modulate autophagy-related factors during cisplatin treatment.

In this study, muscle atrophy was prevented as demonstrated by the downregulation of Atrogin-1 and MuRF 1 in both the CRE and CAE groups (Fig. 4C, D, G, H). In addition, the level of phosphorylation of 4EBP1 in CRE and CAE was increased in both the GAS and SOL muscle samples (Fig. 2B, F). This result is supported by a previous study reporting downregulation of muscle atrophy-related genes, such as those encoding MuRF 1 and Atrogin-1, in the aerobic exercise group [13]. Phosphorylation of 4EBP1 during exercise protects against muscle atrophy by increasing protein synthesis [35,36]. MuRF 1 and Atrogin-1 expression levels were decreased in the CRE and CAE groups, similar to the decreased levels of the autophagy-related factors BNIP3, Beclin 1, and p62 and decrease in the LC3-II/I ratio. Moreover, in tumor-bearing mice, aerobic exercise decreased the mRNA expression level of E3 ligase and levels of autophagy-related proteins as well as improved muscle protein turnover [37-39]. The muscles of patients with cancer cachexia showed increase BNIP3 and LC3 protein levels, suggesting that autophagy can be modulated by using a therapeutic approach [40]. Additionally, both aerobic and resistance exercise-induced FOXO3a expression in patients with cancer undergoing chemotherapy helped maintain the regulation of MuRF 1 and Atrogin-1, which prevented muscle wasting [41]. These findings indicate that exercise directly downregulated FOXO3a expression and de-activated the transcription of genes related to autophagy and muscle atrophy, thereby preventing muscle wasting during cisplatin treatment [26,29-31].

Autophagy and muscle atrophy occurred at similar levels in the GAS and SOL muscles, which is concordant with the results of previous studies showing that chemotherapy treatments caused the loss of type I muscle fibers [34] with no significant change after exercise training [42]. Additionally, in patients with breast cancer subjected to both aerobic and resistance training, MuRF 1 expression was downregulated in both type I and type II muscle fibers [43]. Moreover, in an autophagy knockout model (Atg16L1 mouse), attenuation of ATG16 autophagy proteins was highly correlated with skeletal muscle fiber development [44]. Overall, both the GAS and SOL muscles decreased autophagy expression levels for both exercise and skeletal muscle types (Fig. 5).

Exercise training directly affected the expression of AKT, PGC1-α, and FOXO3a, which modulated autophagy-related factors such as the expression levels of BNIP3, Beclin 1, and p62; the LC3-II/I ratio; and muscle atrophy, reflected by expression levels of MuRF 1 and Atrogin-1. These results suggest that both aerobic and resistance exercise inhibited muscle wasting by upregulating autophagy-related factors and downregulating muscle atrophy factors across different skeletal muscle types following cisplatin administration. Further studies are needed to analyze the effects of exercise on a cancer cachexia model and normal healthy controls.

ACKNOWLEDGEMENTS

We thank Dr. Jeong Rim Ko for establishing the cisplatin-administered animal models. This work was supported by the Ministry of Education of the Republic of Korea and the National Research Foundation (NRF) of Korea (grant number NRF-2018S1A5A807802); Ministry of Science and ICT (grant number 2018R1A2A3074998); Basic Research Lab Program (grant number 2020R1A4A10188943); Ministry of Science, ICT, and Future Planning (grant number 2020M3A9D803866011); and Korea Mouse Phenotyping Project (grant number 2013M3A9D5072560). The funding sources had no involvement in the study design, man-
Exercise modulates autophagy related proteins in cisplatin induced rats

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

REFERENCES

1. Conte E, Bresciani E, Rizzi L, Cappellari O, De Luca A, Torreso A, Liantonio A. Cisplatin-induced skeletal muscle dysfunction: mechanisms and counteracting therapeutic strategies. Int J Mol Sci. 2020;21:1242.

2. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger R, Hall S, Lucey M, Schmidli J, Schneeweiss A, van de Wiel MA, van den Brekel MW, Zahm SH, Ziegler PE. Sarcopenia: definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489-495.

3. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96:857-868.

4. Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Del Piccolo P, Burden SJ, Di Lisi R, Sandri C, Zhao J, Goldberg AL, Schiaffino S, Sandri M. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab. 2007;6:458-471.

5. Galluzzi L, Bachrach E, Ballabio A, Boya P, Bravo-San Pedro JM, Cecconi F, Choi AM, Chu CT, Codogno P, Colombo M, Cuervo AM, Debnath J, Deretic V, Dikic I, Espejo EL, Fimia GM, Fulda S, Gewirtz DA, Green DR, Hansen M, et al. Molecular definitions of autophagy and related processes. EMBO J. 2017;36:1811-1836.

6. Dehoux M, Van Beneden R, Pasko N, Lause P, Verniers J, Underwood L, Ketelslegers JM, Thissen JP. Role of the insulin-like growth factor I decline in the induction of atrogin-1/MAFbx during fasting and diabetes. Endocrinology. 2004;145:4806-4812.

7. Clavel S, Coldefy AS, Kurkdjian E, Salles J, Margaritis I, Derijard B. Atrophy-related ubiquitin ligases, atrogin-1 and MuRF1 are up-regulated in aged rat Tibialis Anterior muscle. Mech Ageing Dev. 2006;127:794-801.

8. Bresciani E, Rizzi L, Molteni L, Raveli M, Liantonio A, Ben Haj Salah K, Fehrentz JA, Martinez J, Omeljaniuk RJ, Biagini G, Locatelli V, Torreso A. JMV2894, a novel growth hormone secretagogue, accelerates body mass recovery in an experimental model of cachexia. Endocrinology. 2017;58:106-114.

9. Conte E, Camerino GM, Mele A, De Bellis M, Pierro S, Rana F, Fonzino A, Caloiero R, Rizzi L, Bresciani E, Ben Haj Salah K, Fehrentz JA, Martinez J, Giustino A, Mariggiò MA, Coluccia M, Tricario D, Logrando MD, De Luca A, Torreso A, et al. Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin-induced cachexia. J Cachexia Sarcopenia Muscle. 2017;8:386-404.

10. Fanzani A, Zanola A, Rovetta F, Rossi S, Aleo MF. Cisplatin triggers atrophy of skeletal C2C12 myotubes via impairment of Akt signaling pathway and subsequent increment activity of proteasome and autophagy systems. Toxicol Appl Pharmacol. 2011;250:312-321.

11. Lee K, Ochi E, Song H, Nakazato K. Activation of AMP-activated protein kinase induce expression of FoxO1, FoxO3a, and myostatin after exercise-induced muscle damage. Biochem Biophys Res Commun. 2015;466:289-294.

12. Luo L, Lu AM, Wang Y, Hong A, Chen Y, Hu J, Li X, Qin ZH. Chronic resistance training activates autophagy and reduces apoptosis of muscle cells by modulating IGF-1 and its receptors, Akt/mTOR and Akt/FOXO3a signaling in aged rats. Exp Gerontol. 2013;48:427-436.

13. Hojman P, Fjelbye J, Zerahn B, Christensen JF, Dethlefsen C, Lonkvist CK, Brandt C, Gislé H, Pedersen BK, Gehr J. Voluntary exercise prevents cisplatin-induced muscle wasting during chemotherapy in mice. PLoS One. 2014;9:e109030.

14. Miyagi MY, Seelaender M, Castoldi A, de Almeida DC, Baccarau AV, Andrade-Oliveira V, Enju LM, Pisciottano M, Hayashida CY, Hiyane M, Brum PC, Camara NO, Amano MT. Long-term aerobic exercise protects against cisplatin-induced nephrotoxicity by modulating the expression of IL-6 and HO-1. PLoS One. 2014;9:e108543.

15. Sirago G, Conte E, Fracasso F, Cormio A, Fehrentz JA, Martinez J, Musico C, Camerino GM, Fonzino A, Rizzi L, Torreso A, Lezza AMS, Liantonio A, Cantatore P, Pesce V. Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia. Sci Rep. 2017;7:13017.

16. Li T, Wei S, Shi Y, Pang S, Qin Q, Yin J, Deng Y, Chen Q, Wei S, Nie S, Liu L. The dose-response effect of physical activity on cancer mortality: findings from 71 prospective cohort studies. Br J Sports Med. 2016;50:339-345.

17. Tong CKW, Lau B, Davis MK. Exercise training for cancer survivors. Curr Treat Options Oncol. 2020;21:53.

18. Fernández de Mattos S, Villalonga P, Clarke J, Lam EW. FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells. Mol Cancer Ther. 2008;7:3237-3246.

19. Lu M, Chen X, Xiao J, Xiang J, Yang L, Chen D. FOXO3a reverses the cisplatin resistance in ovarian cancer. Arch Med Res. 2018;49:84-88.

20. Rashtchizadeh N, Argani H, Ghorbanihagho A, Sanadou J, Hosseini V, Dastmalchi S, Nazari Soltan Ahmad S. AMPK: a promising molecular target for combating cisplatin toxicities. Biochem Pharmacol. 2019;163:94-100.

21. Zeng Z, Liang J, Wu L, Zhang H, Lv J, Chen N. Exercise-induced autophagy suppresses sarcopenia through Akt/mTOR and Akt/FOXO3a signal pathways and AMPK-mediated mitochondrial quality control. Front Physiol. 2020;11:583478.

22. Sun M, Huang C, Wang C, Zheng J, Zhang P, Xu Y, Chen H, Shen W. Ginsenoside Rg3 improves cardiac mitochondrial population quality: mimetic exercise training. Biochem Biophys Res Commun. 2013;441:169-174.

23. Kim HJ, So B, Choi M, Kang D, Song W. Resistance exercise training increases the expression of irisin concomitant with improvement of muscle function in aging mice and humans. Exp Gerontol. 2015;70:11-17.

24. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004;117:399-412.
25. Sandri M. Autophagy in skeletal muscle. FEBS Lett. 2010;584:1411-1416.

26. Brandt N, Gunnarsson TP, Bangsbo J, Pilegaard H. Exercise and exercise training-induced increase in autophagy markers in human skeletal muscle. Physiol Rep. 2018;6:e13651.

27. Sakai H, Kimura M, Isa Y, Yabe S, Maruyama A, Tsuruino Y, Kai Y, Sato F, Yumoto T, Chiba Y, Narita M. Effect of acute treadmill exercise on cisplatin-induced muscle atrophy in the mouse. Pflugers Arch. 2017;469:1495-1505.

28. Stefanetti RJ, Lamon S, Wallace M, Vendelbo MH, Russell AP, Vissing K. Regulation of ubiquitin proteasome pathway molecular markers in response to endurance and resistance exercise and training. Pflugers Arch. 2015;467:1523-1537.

29. Vainshtein A, Hood DA. The regulation of autophagy during exercise in skeletal muscle. J Appl Physiol (1985). 2016;120:664-673.

30. Zhao J, Brault JJ, Schild A, Goldberg AL. Coordinate activation of autophagy and the proteasome pathway by FoxO transcription factor. Autophagy. 2008;4:378-380.

31. Zhao J, Brault JJ, Schild A, Cao P, Sandri M, Schiaffino S, Lecker SH, Goldberg AL. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab. 2007;6:472-483.

32. van der Vos KE, Eliasson P, Proikas-Cezanne T, Vervoort SJ, van Boxtel R, Putker M, van Zutphen JJ, Mauthe M, Zellmer S, Pals C, Verhagen LP, Gebhardt R, Burgering BM, Coffer PJ. Modulation of glutamine metabolism by the PI(3)K-PKB-FOXO network regulates autophagy. Nat Cell Biol. 2012;14:829-837.

33. Milan G, Romanello V, Pescatore F, Armani A, Paik JH, Frasson L, Seydel A, Zhao J, Abraham R, Goldberg AL, Blaauw B, DePinho RA, Sandri M. Regulation of autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network during muscle atrophy. Nat Commun. 2015;6:6670.

34. Christensen JF, Jones LW, Tolver A, Jørgensen LW, Andersen JL, Adamsen L, Højman P, Nielsen RH, Rørth M, Daugaard G. Safety and efficacy of resistance training in germ cell cancer patients undergoing chemotherapy: a randomized controlled trial. Br J Cancer. 2014;111:8-16.

35. Saran U, Guarino M, Rodriguez S, Simillion C, Montani M, Foti M, Humar B, St-Pierre MV, Dufour JF. Anti-tumoral effects of exercise on hepatocellular carcinoma growth. Hepatol Commun. 2018;2:607-620.

36. White JP, Puppa MJ, Gao S, Sato S, Welle SL, Carson JA. Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK. Am J Physiol Endocrinol Metab. 2013;304:E1042-E1052.

37. Hardee JP, Counts BR, Carson JA. Understanding the role of exercise in cancer cachexia therapy. Am J Lifestyle Med. 2017;11:46-60.

38. Salomão EM, Moneto AT, Silva GO, Gomes-Marcondes MC. Physical exercise and a leucine-rich diet modulate the muscle protein metabolism in Walker tumor-bearing rats. Nutr Cancer. 2010;62:1095-1104.

39. Pigna E, Berardi E, Aulino P, Rizzuto E, Zampieri S, Carraro U, Kern H, Merigliano S, Grasso A, Merigallay M, Li Z, Rocchi M, Barone R, Macaluso F, Di Felice V, Adamo S, Coletti D, Moresi V. Aerobic exercise and pharmacological treatments counteract cachexia by modulating autophagy in colon cancer. Sci Rep. 2016;6:26991.

40. Aversa Z, Pin F, Lucia S, Penna F, Verzaro R, Fazi M, Colasante G, Tirone A, Rossi Fanelli F, Rammaccini C, Costelli P, Muscaritoli M. Autophagy is induced in the skeletal muscle of cachectic cancer patients. Sci Rep. 2016;6:30340.

41. Møller AB, Lambro S, Farup J, Voss TS, Rittig N, Wang J, Hojris I, Mikkelsen UR, Jessen N. Molecular and cellular adaptations to exercise training in skeletal muscle from cancer patients treated with chemotherapy. J Cancer Res Clin Oncol. 2019;145:1449-1460.

42. Toth MJ, Callahan DM, Miller MS, Tourville TW, Hackett SB, Couch ME, Dittus K. Skeletal muscle fiber size and fiber type distribution in human cancer: effects of weight loss and relationship to physical function. Clin Nutr. 2016;35:1359-1365.

43. Mijwel S, Cardinale DA, Norrbom J, Chapman M, Ivarsson N, Wengström Y, Sundberg CJ, Randqvist H. Exercise training during chemotherapy preserves skeletal muscle fiber area, capillarization, and mitochondrial content in patients with breast cancer. FASEB J. 2018;32:5495-5505.

44. Paolini A, Omairi S, Mitchell R, Vaughan D, Matsakas A, Vaiyapuri S, Ricketts T, Rubinsztein DC, Patel K. Attenuation of autophagy impacts on muscle fibre development, starvation induced stress and fibre regeneration following acute injury. Sci Rep. 2018;8:9062.